'Market unlikely to fall below August lows; expect strong returns from private banks, paints stocks' Private banks will outperform market and will generate maximum returns, due to strong revenue growth along with stable NII's (Net interest income).
Market Headstart: Nifty likely to open gap down; Kansai Nerolac, Fine Organic top buys Trends on SGX Nifty indicate a negative opening for the broader index in India, with a 54 points loss from closing figure of 1st October (11,396).
Podcast | Stock picks of the day: Volatility is likely to grip market within the range of 11,500-11,200 From the technical front, the Nifty is still holding above its long-term moving averages and as far as prices are holding above 11,200 mark, we expect that the volatility is likely to grip the market within the broader range of 11,500-11,200.
A morning walk down Dalal Street: Bears could tighten grip is Nifty slips below 11,246 As long as the index trades below 11,400 levels and if it breaks Tuesday's intraday low of 11246, then the bears could tighten their grip at Dalal Street, experts feel.
Stocks in the news: Biocon, Petronet LNG, Hero Moto, Alkem Lab, PNB, Cipla, Torrent Pharma Petronet LNG | Hero MotoCorp | Torrent Pharmaceuticals| Reliance Capital | HEG | PNB and Canara Bank are among stocks which are in news today.
Accumulate Kansai Nerolac Paints; target of Rs 479: Prabhudas Lilladher Prabhudas Lilladher recommended accumulate rating on Kansai Nerolac Paints with a target price of Rs 479 in its research report dated July 29, 2019.
Kansai Nerolac Paints falls 4% after CLSA maintained ‘Sell’ despite strong Q1 show On sequential basis, EBITDA margin expanded by 400 bps and gross margin increased by 300bps. CLSA had estimated EBITDA at Rs 189 crore.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.